Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации8364UnclassifiedNT-PROBNP LEVELS IN PATIENTS WITH COVID-19 AND HFGlavatskikhYuliya O.Yuliyag36@gmail.comhttps://orcid.org/0000-0002-2398-5987TokmachevRoman Е.r-tokmachev@mail.ruhttps://orcid.org/0000-0001-6379-4635BudnevskayaSofia А.yuliyag36@gmail.comhttps://orcid.org/0000-0003-3649-5642DrobyshevaValeria R.drobyshevavr@gmail.comhttps://orcid.org/0000-0001-6636-6644Voronezh State Medical University named after N. N. Burdenko2004202312S26466481402202313042023Copyright © 2023, Glavatskikh Y.O., Tokmachev R.Е., Budnevskaya S.А., Drobysheva V.R.2023<p><strong><span lang="EN-US">Relevance</span></strong><span class="apple-converted-space"><span lang="EN-US"></span></span><span lang="EN-US">Since the beginning of the pandemic, the number of coronavirus infections has reached 662,221,274. These figures are largely due to the decompensation of heart failure as a result of the addition of SARS-CoV 2 infection. </span></p> <p><strong><span lang="EN-US">Objective</span></strong><span class="apple-converted-space"><span lang="EN-US"></span></span><span lang="EN-US">To study the level of NT-proBNP in patients with chronic heart failure who have had COVID-19.</span></p> <p><strong><span lang="EN-US">Materials and methods</span></strong><span class="apple-converted-space"><span lang="EN-US"></span></span><span lang="EN-US">The study included patients aged 40 to 70 years diagnosed with CHF hospitalized with<span class="apple-converted-space"></span>SARS-C</span>о<span lang="EN-US">V-2 (n=60). The control group consisted of patients hospitalized withSARS-C</span>о<span lang="EN-US">V-2, without signs of HF(n=20). All patients underwent laboratory methods<span class="apple-converted-space"></span></span><span lang="EN">with determination of NT-proBNP levels.</span></p> <p><strong><span lang="EN-US">Results</span></strong><span class="apple-converted-space"><span lang="EN-US"></span></span><span lang="EN-US">The average NT-proBNP level in patients with CHF and Covid-19 was significantly higher than its value in patients without a history of CVD. The ratio of the odds of a favorable course of CHF and Covid-19 or the transfer to the ICU of patients with CHF and Covid-19 depending on the level of Nt-proBNP was studied. The probability of not getting into the ICU in patients with an NT-proBNP level below the threshold is 12.27 times lower than in patients with an Nt-proBNP level of ˃300 pg/ml. Also, the ratio of the chances of a favorable course of CHF and Covid-19 or death depending on the level of Nt-proBNP was studied. The probability of non-occurrence of such a checkpoint as death in patients with an NT-proBNP level below the threshold is 2.43 times lower than in patients with an Nt-proBNP level of ˃300 pg/ml.</span></p> <p><strong><span lang="EN-US">Conclusion.</span></strong><span class="apple-converted-space"><span lang="EN-US"></span></span><span lang="EN-US">Threshold values NT-proBNP for stratification, isolation of risk groups among patients with Covid-19, CHF and Covid-19 have been determined. In patients with Covid-19 and CHF, a strong association has been found between high levels of Nt-proBNP and a negative short-term prognosis (ICU transfer/death).</span></p>chronic heart failurecovid-19cardiac biomarkersNT-proBNP1.Budnevsky AV, Shurupova AD, Kravchenko AY, Tokmachev RE. Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure. Terapevticheskii arkhiv. 2019;91(3):36–41.2.Banin I, Budnevsky A, Grechkin V. et al. The experience of surfactant therapy in severe COVID-19 pneumonia: A case report. International Journal of Biomedicine. 2021;11(2):177–80.3.Tokmachev R, Kravchenko A, Budnevsky A et al. Features of the functional status and cytokine profile of patients with chronic heart failure in combination with chronic obstructive pulmonary disease. International Journal of Biomedicine. 2021;11(1):9–13.4.Коморбидность хронической сердечной недостаточности и хронической обструктивной болезни легких / Ю. О. Главатских, Р. Е. Токмачев, Е. С. Дробышева [и др.] // Forcipe. – 2021. – Т. 4, № S1. – С. 825. – EDN HDENUS.5.Диагностические, прогностические и терапевтические возможности использования теста 6-минутной ходьбы у пациентов с хронической сердечной недостаточностью / Будневский А.В., Кравченко А.Я., Токмачев Р.Е. [и др.]// Кардиоваскулярная терапия и профилактика. 2020;19(6):2460. https://doi.org/10.15829/1728-8800-2020-2460